

Fallberichte in der Misteltherapie

Paul G. Werthmann



12. September 2019, Zürich




Institut für Infektionsprävention und Krankenhaushygiene
Uni-Zentrum für Naturheilkunde
Universitätsklinikum Freiburg • Universität Freiburg



Institut für angewandte Erkenntnistheorie
und medizinische Methodologie
An-Institut der Universität Witten/Herdecke



Übersicht über das Projekt Fallberichte in der Misteltherapie



Suchstrategie nach besondere Fällen

Kontakte der Studie


„Qualitative Mistelstudie: Individuelle onkologische Misteltherapie durch speziell befähigte Ärzte“

Darstellungen auf Fortbildungen der GAÄD
z.B. Onkologie-Tagung


Kontakte auf Tagungen etc.

Mail-Forum der GAÄD (forum-AM)

Wie erfolgt die Ausarbeitung?




Validitäts- und Relevanzprüfung



Lenz et al. JGLD. 2011; 20(4):389-396.




Validität von Fallberichten




Markiert Mitosen. Zytoplasmatisch saures Gliafaserprotein und fortsatztragend MAP2 exprimierende gliale Zellen mit hoher Proliferationsrate.

Patientin mit Diagnose „Glioblastom“ mit einer Überlebenszeit von 6 Jahren unter integrativer Therapie



Validität von Fallberichten



Papilläres,
seröses
Adeno-
karzinom
des rechten
Ovars

Patientin mit Diagnose Adenokarzinom des Ovars, Überlebenszeit von 12 Jahren unter alleiniger Misteltherapie nach Operation

51-jährige Patientin, Diagnose Adenokarzinom des Ovars, Adnektomie und Netzresektion. Überraschend guter Verlauf bei primär schlechter Prognose bei postoperativ noch vorhandenen Tumoranteilen unter Misteltherapie ohne Chemotherapie mit einer Nachbeobachtungszeit von mehr als 12 Jahren.

Histologische Kontrolle


... Heute würde man vermutlich einen serösen Borderlinetumor des Ovars mit invasiven und nicht-invasiven peritonealen Implants diagnostizieren.

Differentialdiagnostisch könnte man noch über ein low grade seröses Adenokarzinom diskutieren.

Ein high grade seröses Adenokarzinom liegt aber nicht vor.

Validität von Fallberichten

Patientin mit Diagnose M.
Hodgkin,
Vollständige Remission
unter alleiniger
Misteltherapie



Histologische Kontrolle

Zusammenfassend sind die Kriterien zur Diagnose einer Lymphom-Infiltration nicht erfüllt. Es handelt sich allerdings tatsächlich um einen sehr schwierigen und ungewöhnlichen Fall. Letztendlich wurden ähnliche Fälle erst im Jahre 2011 ausführlich beschrieben und würden gemäss heutigem Wissensstand als "altersabhängige, EBV-assoziierte polymorph-nodale Lymphoproliferation" bezeichnet werden (vgl. Dojcinov S et al, Blood 2011; 117 (18): 4726ff).

Publikationen

<p>Werthmann PG, Kempenich R, Lang-Avérous G, Kienle, Gunver S. Long-term Survival of a Patient With Advanced Pancreatic Cancer Under Adjunct Treatment With <i>Viscum album</i> Extracts – A Case Report. World J Gastroenterol. March 2019. doi:10.3748/wjg.v25.i12.0000</p>	3.365
<p>Werthmann PG, Kindermann L, Kienle GS. Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with <i>Viscum album</i> Extracts. Complementary Medicine Research. March 2019;1-4. doi:10.1159/000496866</p>	1.053 (2013 for Forsch KimplMed)
<p>Werthmann PG, Kempenich R, Kienle GS. Long-Term Tumor-Free Survival in a Patient with Stage IV Epithelial Ovarian Cancer Undergoing High-Dose Chemotherapy and <i>Viscum album</i> Extract Treatment: A Case Report. The Permanente Journal. 2019;23. doi:10.7812/TPP/18-025</p>	-
<p>Werthmann PG, Inter P, Welsch T, et al. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/ Mitomycin, high-dose, fever inducing <i>Viscum album</i> extracts and subsequent R0 resection: A case report. Medicine. 2018;97(49):e13243. doi:10.1097/MD.00000000000013243</p>	1.804
<p>Reynel M, Villegas Y, Kiene H, Werthmann PG, Kienle GS. Intralesional and subcutaneous application of <i>Viscum album</i> L. (European mistletoe) extract in cervical carcinoma in situ: A CARE compliant case report. Medicine. 2018;97(48):e13420. doi:10.1097/MD.00000000000013420</p>	1.804
<p>Gutsch J, Werthmann PG, Rosenwald A, Kienle GS. Complete Remission and Long-term Survival of a Patient with a Diffuse Large B-cell Lymphoma Under <<i>Viscum album</i>> Extracts After Resistance to R-CHOP: A Case Report. Anticancer Research. 2018;38(9):5363-5369. doi:10.21873/anticanres.12865</p>	1.937
<p>Werthmann PG, Huber R, Kienle GS. Durable clinical remission of a skull metastasis under intralesional <i>Viscum album</i> extract therapy: Case report. Head & Neck. June 2018. doi:10.1002/hed.25320</p>	2.471
<p>Werthmann PG, Kindermann L, Kienle GS. A 21-year course of Merkel cell carcinoma with adjuvant <i>Viscum album</i> extract treatment: A case report. Complementary Therapies in Medicine. April 2018. doi:10.1016/j.ctim.2018.04.001</p>	2.084
<p>Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under <i>Viscum album</i> and <i>Helleborus niger</i> extracts—a case report. Journal of Thoracic Disease. 2017;3(2). doi:10.21037/jtd.2017.11.56</p>	2.365
<p>Werthmann PG, Hintze A, Kienle GS. Complete remission and long-term survival of a patient with melanoma metastases treated with high-dose fever-inducing <i>Viscum album</i> extract: A case report. Medicine. 2017;96(46):e8731. doi:10.1097/MD.00000000000008731</p>	1.804

Tumorentitäten der Publikationen

Lymphom

Malignes Melanom

Merkelzellkarzinom

Nierenzellkarzinom

Ovarialkarzinom

Pankreaskarzinom (2 Fallberichte)

Pleuramesotheliom

Schädelmetastase

Ergebnisse der Publikationen

	Tumor- regression	Langzeit- überleben	Lebensqualitäts- verbesserung
Lymphom	●	●	●
Malignes Melanom	●	●	●
Merkelzellkarzinom		●	●
Nierenzellkarzinom	●	●	●
Ovarialkarzinom		●	●
Pankreaskarzinom (A)	●	●	●
Pankreaskarzinom (B)		●	●
Pleuramesotheliom	●	●	●
Schädelmetastase	●	●	●

Besonderheiten der Publikationen

Lymphom

Vollständige Remission nach Chemotherapie-Resistenz (R-CHOP)

Malignes Melanom

Vollständige Remission von Melanom-Metastasen

Merkelzellkarzinom

Langzeitüberleben von 21 Jahren unter chirurgischer Therapie und Misteltherapie

Nierenzellkarzinom

Vollständige Remission unter Immunochemotherapie und Misteltherapie

Ovarialkarzinom

Langzeitüberleben von 20 Jahren unter chirurgischer Therapie und Misteltherapie

Pankreaskarzinom (A)

Teilremission und Langzeitüberleben unter lokaler fieberinduzierender Misteltherapie

Pankreaskarzinom (B)

Langzeitüberleben von 5 Jahren (63 Monaten) unter Bestrahlung, Chemotherapie, Radiofrequenzablation und Misteltherapie

Pleuramesotheliom

Teilremission und Langzeitüberleben (56 Monate) unter Helleborus niger- und Misteltherapie

Schädelmetastase

Teilremission und Langzeitüberleben unter intratumoraler Misteltherapie

Zur Therapie

	Hersteller	Wirtsbäume	subcutan	intravenös	intralesional
Lymphom	Helixor	Pini	x	x	
Malignes Melanom	Iscador	Mali, Mali spez, Quercus, Quercus F, Pini	x	x	x
Merkelzellkarzinom	Helixor	Abietis	x		
Nierenzellkarzinom	Helixor	Abietis	x	x	
Ovarialkarzinom	Iscador	Mali, Pini	x		
Pankreaskarzinom (A)	Abnoba, Iscucin	Fraxini, Salicis	x		x
Pankreaskarzinom (B)	Iscador	Quercus	x		
Pleuramesotheliom	Abnoba, Helixor, Iscador	Pini, Fraxini	x	x	
Schädelmetastase	Abnoba	Fraxini	x		x


Fallberichte über Misteltherapie in der heutigen Medizin

Review

Benefits, pitfalls and risks of phytotherapy in clinical practice in otorhinolaryngology

O. Laccourreye*, A. Werner, L. Laccourreye, P. Bonfils

Service d'otohynolaryngologie et de chirurgie cervico-faciale, HEGP, université Paris Descartes Sorbonne Paris Cité, AP-HP, 20, rue Leblanc, 75015 Paris cedex 15, France



fundamental findings [67,68]. In Europe, several studies have been conducted on mistletoe. The first, a prospective randomized study of postoperative per os mistletoe extract (with and without radiation therapy) in head and neck squamous cell carcinoma, found no benefit in terms of 5-year survival [69]; this was borne out in a 2008 Cochrane analysis of 21 randomized studies of mistletoe in oncology [70]. Alongside per os administration, there have been three recent case reports of benefit for intratumoral injection of mistletoe extract marketed as Abnoba viscum® in head and neck carcinoma inaccessible to surgery or curative radiation therapy [71–73]. All three reported resolution, of squamous cell or cystic adenoid carcinoma, without recurrence at several months or years; the cytotoxic effect was attributed to activation of apoptosis, leading to cell necrosis, with efficacy varying according to tumor cell line and type of extract [74]. Finally, traditional Chinese phytotherapy did not

Fallberichte über Misteltherapie in der heutigen Medizin

Herbal Medicine and Oral Health: A Review

Soussan Irani^{1,2}

Table 1: The effect of herbal medicine in oral health.

Microbiome	Dental caries	Gingivitis and periodontitis	Oral disease	Oral cancer
<i>Streptococcus sobrius</i>	<i>Rhus coriaria</i> L.	Pomegranate extract (<i>P. granatum</i>)	Jinlianqingre Effervescent	Pterostilbene
<i>Streptococcus mutans</i>	Emodin	Chamomile extract	Reduning	<i>Vitis vinifera</i>
<i>Streptococcus gallinarum</i>		Rokumigan	Baikal skullcap	Insect tea
<i>Streptococcus sanguinis</i>		Canavanine	Oxitarid	Iranian orthodox black tea
<i>Streptococcus salivarius</i>			Ginger	Scutellariae radix
<i>Streptococcus mitis</i>			Chamomilla tincture	Saussurea lappaceae
<i>Streptococcus thermophilus</i>			Quercetin	European <i>Viscum album</i> extract
<i>Streptococcus pyogenes</i>			Zeng Ye decoction	
<i>Streptococcus pneumoniae</i>			<i>Malva sylvestris</i> L.	
<i>Streptococcus faecalis</i>			<i>Alcea digitata</i> (Boiss) Alef	
<i>Streptococcus lactis</i>			Huangqi granule	





www.pancreatica.org

Pancreatica

Confronting Pancreatic Cancer

MAKE AN
IMPACT

Click here for more information !



HOME
PANCREATIC CANCER
BLOG
LINKS
STORIES
ABOUT US
DONATE
GET INVOLVED

Search...

ALTERNATIVE, COMPLEMENTARY AND HOLISTIC TREATMENT

Although we understand the possible benefits of some alternative, complementary, or holistic treatment, this website is not strongly oriented this way. On an anecdotal basis, we have heard of positive experiences that patients have had with the treatment of symptoms related to pancreatic cancer (ductal adenocarcinoma of the pancreas) and chemotherapy involving such approaches as visualization techniques, meditation, prayer, acupuncture, massage, biofeedback, relaxation therapy, hypnotherapy acupuncture, green tea and Chinese herbs.

We are not averse to alternative, complementary, or holistic treatment modalities for pancreatic cancer in which the downsides are weighed against the benefits. This website is oriented to the treatment of pancreatic cancer, but we encourage though not endorse and/or holistic treatment.

Our science board is composed of:

James Abbruzzese, MD Chief, Medical Oncology
Duke University

Markus Büchler, MD Chairman, Surgery
Heidelberg University, Germany

Ralph Hruban, MD Director, GI / Liver Pathology
Johns Hopkins University

Eileen O'Reilly, MD Associate Director for Clinical Research – Memorial Sloan-Kettering Cancer Center

Margaret Tempero, MD Chief, Medical Oncology
University of California at San Francisco

PANCREATICA BLOG ARTICLES

- FOLFIRINOX + Mistletoe

More Here
- Ocimum Sanctum Leaves for Pancreatic Cancer Treatment?

More Here
- Does Aspirin Prevent Pancreatic Cancer? High dose vs. Low Dose Intake

More Here
- Microwave "Surgery" for Pancreatic Cancer

More Here
- Mistletoe for Pancreatic Cancer

More Here
- Eat the Beet (for pancreatic cancer)

More Here
- Pancreatic Cancer Pre-clinical study (from an Amazonian tree): Geissospermum vellosii

More Here
- Momordica Charantia (Bitter Melon) Juice Shows Promise with Pancreatic Cancer Cells and in Mice

More Here

Fallberichte zur Misteltherapie von anderen Autoren



Clinical Case Report

Medicine
OPEN

Prolonged stabilization of platinum-refractory ovarian cancer in a single patient undergoing long-term Mistletoe extract treatment

Case report

Woo Yeon Hwang, MD, Mi Hyun Kang, MD, Seul Ki Lee, MD, Ji Su Yeom, MD, Min Hyung Jung, MD, PhD*

Abstract
Rationale: Advanced ovarian malignancies are associated with poor overall survival; thus, patients often turn to alternative treatments, despite the controversy surrounding their use. Mistletoe extract has been commonly used as complementary medicine to treat patients with cancer for several decades, and has proven benefits in integrative oncology.

Patient concerns: A 47-year-old woman with stage IVB ovarian cancer who underwent optimal surgical cytoreduction, but whose disease persisted after subsequent platinum-based combination chemotherapy and 2nd-line chemotherapy.

Diagnosis and accompanied by 4
Outcomes: The diagnosis and 24
Lessons: Our c
cancer.
Abbreviations:
Keywords: com

Hwang et al. *Medicine* (2019) 98:8



Hwang WY, Kang MH, Lee SK, Yeom JS, Jung MH. Prolonged stabilization of platinum-refractory ovarian cancer in a single patient undergoing long-term Mistletoe extract treatment: Case report. *Medicine*. 2019;98(8):e14536. doi:[10.1097/MD.00000000000014536](https://doi.org/10.1097/MD.00000000000014536)

Unexpected outcome (positive or negative) including adverse drug reactions

CASE REPORT

OPEN ACCESS

Supportive mistletoe therapy in a patient with metastasised neuroblastoma

Jens Kaestner,¹ Dietrich Schlodder,² Christfried Preussler,³ Bernd Gruhn¹

SUMMARY
Therapies of complementary and alternative medicine (CAM) are used increasingly in paediatric oncology. We present and discuss the influence of supportive mistletoe therapy on factors, such as quality of life, physical ability and performance, and course of disease based on the case of a female patient diagnosed at age 12 with neuroblastoma who had received autologous stem cell transplantation. This form of therapy should always be administered in a paediatric oncology setting in controlled therapy-optimisation trials. Alongside such vital standard therapies, complementary oncological procedures are also administered in the treatment of childhood cancer. Among surveyed in a large population-based study, was conducted in cooperation with the Childhood Cancer Registry and included

Figure 3. Timeline of patient care from 2009 to 2018. The timeline shows various treatments and clinical events. Key events include: 2009: diagnosis PNBT, poor general condition (KPI 40%); 2010: CISV chemotherapy, stem cell transplantation, change of diagnosis to neuroblastoma stage IV (multifocal), high dose chemotherapy NB2004 HR, MBG Therapy; 2011: RIST / Zoledronat, therapy termination due to poor tolerance; 2012: Helixor A (1.25-12.5 mg), no change in tumor mass; 2013: Helixor A (1.25-12.5 mg), further tumor progression but good general condition; 2014: Helixor A (1.25-12.5 mg), good general condition, nearly symptom-free; 2017: Radiotherapy (06/2017-07/2017), soft tissue metastasis left temporal bone; 2018: Helixor A (from 06/2018), metastasis left mandible, radiotherapy (01/2018), metastasis left humerus and scapula.


Kaestner J, Schlodder D, Preussler C, Gruhn B. Supportive mistletoe therapy in a patient with metastasised neuroblastoma. *BMJ Case Reports*. 2019;12(3):e227652. doi:[10.1136/bcr-2018-227652](https://doi.org/10.1136/bcr-2018-227652)


2019



2019

Patientin mit Melanom-Metastasen und vollständiger Remission unter alleiniger Misteltherapie

Medicine










3. Antecedent and concomitant therapies

In this case, high-dose VAE therapy was used within an individualized therapy concept of integrative anthroposophic medicine.^[28] No other cancer-specific medical treatments were used.

The patient also suffered from advanced osteochondrosis intervertebralis, goiter, and migraine. Fourteen years before the initial diagnosis of MCM, the patient had been diagnosed with carcinoma in situ of the cervix, which was treated with laser conization. Forty-three years before diagnosis with MCM, she suffered a cranial base fracture.


The patient participated in seminars on mental healing, provided by her health insurance, where she worked on negative life events from her early childhood.^[29] In addition to nutritional supplements containing sodium, calcium, potassium, and magnesium, the patient took fish oil capsules.



Patientenperspektive

„Nach der Diagnose der Metastasen wurde mir im Unispital gesagt, dass ich einen Monat Zeit hätte, bevor die weitere Therapie geplant würde. In dieser Zeit lernte ich die intensivierete Misteltherapie und das Spital mit Anthroposophischer Medizin kennen. Ich lernte, dass ich Selbstvertrauen haben und zu meinem Heilungsprozess beitragen konnte. Ich bemerkte, dass es mein eigenes Engagement brauchte um gesund zu werden, und lern-te dankbar zu sein für alles, was in mir gesund war. Das Engagement für meine Gesundheit beinhaltete auch, ein Bewusstsein für meine Biografie zu entwickeln und all das zu entlarven, was an innerer Sabotage in mir lebt. So konnte ich auch einen eigenen Weg in der Therapie finden und gehen – auch wenn es Ärzte gab, die mich über-zeugen wollten, diesen Weg nicht zu gehen. Die Mistel-therapie mit hohem Fieber und Nebenwirkungen sowie die teils schmerzhaften Injektionen konnte ich gut ver-tragen, weil ich mich in der Behandlung sicher fühlte.“

Langzeit-Überleben (5 Jahre) eines Patienten mit Pankreaskarzinom unter begleitender Misteltherapie



Langzeit-Überleben (5 Jahre) eines Patienten mit Pankreaskarzinom unter begleitender Misteltherapie









Figure 2 Patient's tumor, haematoxylin and eosin stain.
A: $\times 100$; B: $\times 200$; C: ($\times 400$) invasive mucinous adenocarcinoma;
D and E: ($\times 100$) perineural invasion.


Patient mit Pankreaskarzinom mit Resizierbarkeit und Langzeitüberleben nach Misteltherapie


Medicine



Werthmann PG, Inter P, Welsch T, et al. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection: A case report. *Medicine*. 2018;97(49):e13243.

Immunochemotherapie beim Nierenzellkarzinom: Ein Fallbericht eines Patienten mit Langzeitüberleben unter begleitender Misteltherapie





Submandibular metastasis of the patient: Small monomorphic tumor cells with little cytoplasm; the nuclei are roundish with finely granulated chromatin structure of the chromatin and small nucleoli. Pappenheim stain, 1:200.


Patientin mit Merkelzellkarzinom mit Langzeitüberleben unter Misteltherapie

64 years



Initial diagnosis

MCC, left forearm 1x0.4 cm >> Surgical excision



Course of the Viscum album extract (VAE) therapy

Month	VAE Series ^a (mg)	Application	Number of Applications ^b
1 ^c -4	I (1/5/10)	3x/Week	42
5-6	II (10/20/30)	3x/Week	14
6-24	IV (20/30/50)	3x/Week	182
25-74	IV (20/30/50)	2x/Week	168
74-86	Treatment Break		
87-156	IV (20/30/50)	2/Week	476
157-160	Treatment Break		
161-192	IV (20/30/50)	2/Week	210
193-228 ^d	IV (20/30/50)	2 Cycles per Year	84
			Total: 1176

^a I: Helixor[®] A (from the host tree fir) Serie I contains 7 vials of lower dosage (3 × 1 mg/mL, 3 × 5 mg/mL, 1 × 10 mg/mL); II: Serie II contains 7 vials of medium dosage (2 × 10 mg/mL, 2 × 20 mg/mL, 3 × 30 mg/mL); IV: Serie IV contains 7 vials of higher dosage (2 × 20 mg/mL, 2 × 30 mg/mL, 3 × 50 mg/mL).

^b Applications were carried out as 7 subcutaneous injections in increasing dosages (Series I, II or IV) followed by 7 injections in decreasing dosages (Series I, II or IV, each backwards), with a subsequent treatment break of 2 weeks.

^c Month 1 of the VAE therapy = Month 25 after the initial diagnosis.

^d Until the date of publication.

Werthmann PG, Kindermann L, Kienle GS. A 21-year course of Merkel cell carcinoma with adjuvant Viscum album extract treatment: A case report. *Complementary Therapies in Medicine*. April 2018

Abbreviations: I/II/IV: Helixor[®] A Series I/II/IV; 3/w: three injections per week; 2/w: two injections per week; 2c/y: two cycles of 14 injections per year; MCC: Merkel cell carcinoma; for details of the treatment with Viscum album extracts see Table.


*Treatment intermission of 4 months due to a fall with femoral neck fracture and subdural hematoma and subsequent treatment.

Patientin mit Schädelmetastase mit Rückbildung unter alleiniger intratumoraler Misteltherapie



Foto (A) and MRI (B) of the parietal lesion


Remitted parietal lesion



*Red dots indicate new metastatic lesions or significant progression; AVF: AbnobaViscum® Fraxini (host tree: ash); 2x/M: two intralesional injections per month; 1x/M: one intralesional injection per month; **cycle 3-6 with dose reduction due to repeated neutropenia

2.2 | Patient perspective (from a television interview)

"[My] whole well-being has changed, and I've got more power to do my things. Beforehand, there were days where I felt completely powerless and I wanted to give up. The mistletoe treatment helped me there."²²



*Red dots indicate new metastatic lesions or significant progression; AVF: AbnobaViscum® Fraxini (host tree: ash); 2x/M: two intralesional injections per month; 1x/M: one intralesional injection per month; **cycle 3-6 with dose reduction due to repeated neutropenia



Patientin mit Pleuramesotheliom mit Langzeitüberleben unter Misteltherapie





Table 1 IAM therapy with VAE and HNE

Month	Viscum album extract (VAE)	Helleborus niger extract (HNE)
0	-	-
1	-	-
Week 1-2	Abnobaviscum Pini D10 sc eod	Helleborus niger D3 sc eod
Week 3-4	Helixor Pini 1-10 mg sc eod	-
2-3	Helixor Pini 1-10 mg sc 2/w	Helleborus niger D3; sc 2/w
4-8	Helixor Pini 10-30 mg sc 2/w	-
9-14	Helixor Pini 100 mg sc 2/w	-
15-16	-	-
17-20	Helixor Pini 100 mg sc 2/w	Helleborus niger D6 sc 2/w
21	Helixor Pini 200 mg sc 2/w	-
22-23	Abnobaviscum Fraxini 20 mg sc 2/w Helixor Pini 100 mg sc 2/w	-
24-33	Iscador c/Hg 20 mg sc 2/w Helixor Pini 100 mg sc 1/w	-
34-36	-	-
37-50	Helixor Pini 100 mg iv 1/w	-
51-56	-	-

IAM, Integrative Anthroposophic Medicine; sc, subcutaneous; iv, intravenous; eod, every other day; 1/w, once weekly; 2/w, twice weekly; D3/6/10: dilution 1:10^{3/6/10}.



Werthmann PG, Saltzwedel G, Kienle GS. Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under *Viscum album* and *Helleborus niger* extracts—a case report. *Journal of Thoracic Disease*. 2017;3(2).

Vielen Dank für Ihre Aufmerksamkeit!

Ich danke allen Ärztinnen und Ärzten und insbesondere allen Patientinnen und Patienten für ihre Mitarbeit.

*Ich danke der **Stiftung Integrative Medizin** für die finanzielle Unterstützung unseres Projekts Fallberichte in der Misteltherapie.*

Es besteht kein Interessenskonflikt.

Kontakt: paul.werthmann@ifaemm.de